The four-day 2022 national medical insurance drug catalog negotiation ended in Beijing on August 8. The head of the Medical Management Department of the National Health Insurance Bureau responded to the negotiations on COVID-19 therapeutic drugs: there were three kinds of COVID-19 therapeutic drugs entering the negotiations, among which Azovudine tablets and Qingfei Paidu granules were successfully negotiated, and Pfizer Nematvir/Litonavir combination packaging failed due to high prices. The person in charge said that four departments, including the National Health Insurance Bureau, had recently issued the Notice on Optimizing the Relevant Policies of Medical Insurance for Treatment Expenses of Patients with novel coronavirus Infection after the Implementation of "Class B Management", which clarified that the temporary payment policy for medical insurance will be implemented for COVID-19 treatment drugs included in the diagnosis and treatment plan for COVID-19 infection, and will be implemented first until March 31, 2023. That is to say, the combined packaging of Azovudine tablets, Qingfei Paidu granules and Pfizer Nematvir tablets/Litonavir tablets in this negotiation has been temporarily included in the scope of medical insurance payment, and patients can enjoy relevant medical insurance reimbursement policies before March 31, 2023. In addition, after Azovudine Tablets and Qingfei Paidu Granules were included in the national medical insurance drug list through this negotiation, there were more than 600 kinds of drugs in the national medical insurance drug list for the treatment of fever, cough and other COVID-19 symptoms. The person in charge said that in the near future, local medical insurance departments have temporarily included a batch of COVID-19 symptomatic drugs into the payment scope of local medical insurance in combination with the operation of local medical insurance funds. In general, there are a variety of drugs for COVID-19 infection treatment reimbursed by medical insurance. Next, the State Medical Insurance Bureau will make every effort to adjust the medical insurance drug list, include more new and good drugs in the medical insurance drug list, and effectively reduce the burden of medical care for the masses. It is reported that the final results of the 2022 negotiation on the national medical insurance drug catalog are expected to be released in the near future. (Outlook New Times)